“The three big success stories in the last couple [of] years have been [vitamins] B [and] D and probiotics,” Kurt Jetta, CEO of TABS Group, told DSN. “Adult [multivitamins] from last year are up, although that now has stopped in its tracks because of some negative PR [published in JAMA],” he said. “That usually has a disruptive effect for several months. ... Our research shows it’s up [significantly] due to overall usage.”
Read entire article on Drug Store News
